

# We are IntechOpen, the world's leading publisher of Open Access books Built by scientists, for scientists

**4,800**

Open access books available

**122,000**

International authors and editors

**135M**

Downloads

Our authors are among the

**154**

Countries delivered to

**TOP 1%**

most cited scientists

**12.2%**

Contributors from top 500 universities



**WEB OF SCIENCE™**

Selection of our books indexed in the Book Citation Index  
in Web of Science™ Core Collection (BKCI)

Interested in publishing with us?  
Contact [book.department@intechopen.com](mailto:book.department@intechopen.com)

Numbers displayed above are based on latest data collected.

For more information visit [www.intechopen.com](http://www.intechopen.com)



## DNA Methylation in Acute Leukemia

Kristen H. Taylor and Michael X. Wang  
*University of Missouri-Columbia,  
USA*

### 1. Introduction

After birth, all blood cells are produced in the bone marrow by a process known as hematopoiesis. The basic biological process of hematopoiesis is the differentiation of hematopoietic stem cells (HSCs) to generate different types of mature blood cells (Kawamoto et al., 2010). In an adult, approximately  $10^{12}$  blood cells are produced daily and released into the circulating peripheral blood. As new cells are released, some old cells undergo apoptosis in tissues or cleaned by spleen in order to maintain a homeostatic level of blood cells. Hematopoiesis is highly regulated through the interaction between hematopoietic cells and the bone marrow microenvironment. Many cytokines or growth factors and extracellular matrix molecules that are secreted either from stromal cells or from hematopoietic cells, as well as nutrients and vitamins, provide a favorable microenvironment for hematopoiesis to occur (Metcalf, 2008). Under the influence of specific growth factors such as c-KIT ligand and FLT-3 ligand, after rounds of asymmetric divisions of hematopoietic stem cells (HSCs), some daughter cells participate in lineage-commitment differentiation to become either lymphoid or myeloid progenitors. After several rounds of proliferation, these progenitor cells undergo terminal differentiation becoming mature lymphocytes (B-cells, T-cells and NK-cells) or myeloid cells (granulocytes, monocytes, red blood cells, mast cells and platelets). Generation of lymphocytes and myeloid cells in bone marrow during hematopoiesis is termed as lymphopoiesis and myelopoiesis, respectively. Disruption of these normal physiological processes at the stages of HSCs and/or progenitors may initiate leukemogenesis, a neoplastic transformation, and result in leukemia. Leukemia is classified as acute or chronic leukemia based on the clinical presentation and pathophysiological features. Acute leukemia is classified as acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML) based on the cell lineages. Therefore, ALL may be B-cell, T-cell, or NK-cell in origin, while AML may be a granulocytic, monocytic, erythroid, or megakaryocytic subtype (Swerdlow et al., 2008; Vardiman et al., 2009).

### 2. Clinical aspects of acute leukemia

ALL and AML are the most common leukemias in children and adults, respectively (Siegel et al., 2011). Both diseases are characterized by acute onset and rapid accumulation of immature leukemic cells (blasts) in the bone marrow and blood (>20% of nucleated cells). Leukemic blasts are abnormal because they remain immature and do not function like

mature white blood cells. ALL occurs mainly in children with peak prevalence between the ages of 2 and 5 years. Approximately 3,200 new ALL cases in childhood are diagnosed in the United States each year and two thirds of these cases are the B-cell subtype (Pui et al. 2004). Worldwide, ALL occurs approximately 5 cases per 100,000 populations per year. In contrast, AML occurs mainly in adults aged 65 years or older with a median age of 60 years (Löwenberg et al., 1999; Estey & Döhner, 2006). Approximately 13,400 new AML cases are diagnosed in the United States each year. Incidence of AML is about twice that of ALL worldwide. The prognosis is much poorer for AML than ALL, especially in elderly patients (Estey & Döhner, 2006).

Both ALL and AML are clonal disorders of hematopoietic stem cells (HSCs) or progenitor cells characterized by loss of normal maturation and gain of capacity of uncontrolled proliferation (Pui et al. 2004; Estey & Döhner, 2006; Becker et al. 2010). Leukemic blasts accumulate in blood and bone marrow and replace normal hematopoietic elements in the bone marrow. Furthermore, the blasts can infiltrate other organs and tissues including spleen, liver, lymph nodes and even skin. Most patients with acute leukemia present with the consequences of bone marrow failure presenting as anemia (decreased red blood cells), neutropenia (decreased neutrophils), and thrombocytopenia (decreased platelets). Pancytopenia (decreased all types of blood cells) with circulating blasts is the strong evidence for the diagnosis of acute leukemia. After diagnosis of a specific subtype of acute leukemia with advanced and integrated approaches including clinical information, laboratory data, morphology, immunophenotype (flow cytometry or immunohistochemistry), and genetic tests (cytogenetic karyotype and molecular genetic analysis), an effective chemotherapy regimen must be immediately initiated. The goal of treatment is to eliminate the leukemic blasts, preserve and restore normal hematopoiesis, and to prevent relapse (Bassan & Hoelzer, 2011; Burnett et al., 2011). To avoid the toxicity of chemotherapy, the patients are stratified based on the biological features of leukemia blasts and risk factors of the individual patient (host). In addition to clinical factors (age, gender, leukocyte count, etc.), specific genetic abnormalities, such as chromosomal translocations and/or gene mutations, are the most important factors in determining risk stratification in modern treatment of the leukemia patients (Pui et al., 2011). Although the treatment regimens are different in ALL and AML, a standard protocol typically consists of three phases: a remission-induction phase, an intensification (or consolidation) phase, and a continuation (maintenance) phase (Bassan & Hoelzer, 2011; Burnett et al., 2011). The goal of remission-induction treatment is to eradicate more than 99% of the initial leukemic cell burden and to restore normal hematopoiesis. The intensification treatment is generally aimed to eradicate drug-resistant residual leukemic cells including leukemia stem cells (Becker & Jordan, 2010). The last phase is maintenance chemotherapy for an additional 2.0-2.5 years to reduce the risk of relapse. The regimens usually include several drugs that have different pharmacological mechanisms of action to have maximal efficacy. In addition to routine chemotherapy, allogeneic hematopoietic stem-cell transplantation is the most intensive form of treatment for high risk acute leukemia (Gupta et al., 2010). Compared to various solid tumors, outcomes are excellent for treatment of acute leukemia, especially in young patients. In most large clinical trials, the cure rates are more than 80% and 60% in ALL and AML, respectively (Pui et al., 2011).

### 3. Genetic alterations

Like all other malignancies, acute leukemia is a genetic disease. Specific genetic alterations including chromosomal translocation, deletion, addition, and gene mutations (point mutation, copy number change) have been identified in all ALL and AML cases. These genetic alterations are widely utilized for diagnosis, risk stratification, prediction of response to chemotherapeutic reagents, prognosis and detection of minimal residual disease (Estey & Döhner, 2006; Swerdlow et al., 2008; Pui et al., 2008).

#### 3.1 Genetic alterations in ALL

At the genetic level, ALL is a group of heterogeneous diseases. Standard cytogenetic analyses can detect primary chromosomal abnormalities in more than 70% of ALL cases (Mrózek et al., 2009). Using higher resolution and/or high throughput molecular methods, genetic alterations can be identified in virtually all cases of ALL tested (Mullighan et al., 2007). These alterations include gene rearrangements, gene copy number changes (deletions or duplications) and genomic sequence point mutations. Some of these changes are directly linked with leukemogenesis and affect important cellular pathways in cell differentiation, cell cycle regulation, tumor suppression, and apoptosis. For instance, PAX5, a B-cell specific transcription factor important for B-cell differentiation, was found frequently deleted or mutated in B-ALL (Mullighan et al., 2007). Other changes may be merely “passengers” and irrelevant to the biological properties and leukemogenesis of ALL.

The WHO classification of tumors of hematopoietic and lymphoid tissues (Swerdlow et al., 2008) designates ALL as B- or T-lymphoblastic leukemia/lymphoma based on cell lineages and percentage of the blasts in bone marrow. Each lineage group is further categorized as ALL with recurrent genetic abnormalities and not otherwise specified (NOS) based on identifiable chromosomal abnormalities by routine cytogenetic analysis (Figure 1). B-ALLs with recurrent genetic abnormalities include B-ALL with t(9;22)(q34;q11.2); *BCR-ABL1*, B-ALL with t(v;11q23); *MLL* rearranged, B-ALL with t(12;21)(p13;q22) *TEL-AML1(ETV6-RUNX1)*, B-ALL with hyperdiploidy, B-ALL with hypodiploidy, B-ALL with t(5;14)(q31;q32) *IL3-IGH*, B-ALL with t(1;19)(q23;p13.3); *E2A-PBX1 (TCF3-PBX1)*. Each designation contains the chromosomes involved, chromosomal loci, and the genes as well as alternative gene names. This subgroup accounts for 60% to 80% of B-ALL cases with distinct biologic and pharmacologic features that are important in diagnosis and risk stratification. The remaining B-ALL cases with no identifiable chromosomal abnormalities are characterized on the basis of morphologic and immunophenotypic features Figure 1A. Fifty to seventy percent of T-ALL patients demonstrate abnormal karyotypes. The most common recurrent abnormalities are translocations that involve the alpha and delta T-cell receptor loci at 14q11.2, the beta locus at 7q35, or the gamma locus at 7p14-15, and many partner genes (Pui et al., 2004; Giroux et al., 2006; Swerdlow et al., 2008). The pathological significance of these abnormalities is not as clearly understood as those that are associated with B-ALL.

#### 3.2 Genetic alterations in AML

More than 90% of AML cases have at least one known genomic alteration as demonstrated by current routine cytogenetic or molecular analysis (Löwenberg et al., 1999) Figure 1B.

Using high resolution and high throughput methods, virtually all AML cases are identified as having distinct genetic mutations (Estey & Döhner, 2006; Godley et al., 2011).




Fig. 1. Genetic alterations in ALL and AML. Genetic alterations can occur at either chromosomal level or DNA sequence level. Although some acute leukemia cases have a normal karyotype (A, an ALL patient), there are many mutations detectable at the DNA level. Most acute leukemia cases demonstrate specific chromosomal abnormalities that defined a distinct subtype of ALL or AML with important diagnostic and prognostic applications. The right panel (B) shows a case of acute promyelocytic leukemia (APL) with  $t(15;17)(q22;q12)$ ; *PML-RARA* (with addition at chromosome 7 in this case). APL represents a cytogenetically defined AML that can be treated with less toxic all-*trans* retinoid acid, a metabolite of vitamin A, with a favorable prognosis.

AML is a group of extremely heterogeneous diseases at the genetic level. Based on cytogenetic features and cell lineages, the WHO classification of tumors of hematopoietic and lymphoid tissues classifies AML into seven cytogenetic types with specific genetic abnormalities and nine not otherwise specified (NOS) types based on distinct morphology, cytochemistry and immunophenotype (Figure 1B). Furthermore, two provisional subtypes have been proposed based on point mutations in *NPM1* and *CEBPA* genes (Swerdlow et al., 2008, Vardiman et al., 2009; Döhner, 2010). AML with recurrent genetic abnormalities include AML with  $t(8;21)(q22;q22)$ ; *RUNX1-RUNX1T1*, AML with  $inv(16)(p13.1q22)$  or  $t(16;16)(p13.1;q22)$ ; *CBFB-MYH11*, APL with  $t(15;17)(q22;q12)$ ; *PML-RARA* (Figure 1B), AML with  $t(9;11)(p22;q23)$ ; *MLLT3-MLL*, AML with  $t(6;9)(p23;q34)$ ; *DEK-NUP214*, AML with  $inv(3)(q21q26.2)$  or  $t(3;3)(q21;q26.2)$ ; *RPN1-EV11*, AML (megakaryoblastic) with  $t(1;22)(p13;q13)$ ; *RBM15-MKL1*. The chromosomes, loci and the genes are indicated in each specific designation. Many of these chromosomal translocations result in fusion proteins with altered functions of transcription factors critical for normal hematopoiesis and myeloid differentiation (Sternberg & Gilliland, 2004). These cytogenetic abnormalities also have important diagnostic and therapeutic implications. In contrast, the cases with mutations in nucleophosmin (*NPM1*), CCAAT/enhancer binding protein  $\alpha$  (*CEBPA*), Fms-like tyrosine kinase (*FLT3*) and *KIT* genes have been associated with prognosis. More than half of these cases with the gene mutations have normal karyotypes (Marcucci et al., 2005; Foran, 2010).



New approaches such as whole-genome sequencing, gene expression and microRNA profiling, proteomics and genome-wide DNA methylation profiling will not only identify all known mutations and epigenetic alterations, but can also potentially identify novel mutations and epigenetic lesions in biological pathways at the individual level (Boehm & Hahn, 2011). Deciphering the interactions between genetic and epigenetic alterations and expression profile will further provide a comprehensive and high resolution blueprint of leukemogenesis. That information, in turn, will be applied in clinical management of AML patients in the future.

Over the past few years, high-throughput next generation DNA sequencing (NGS) technologies have revolutionized the field of cancer genomics including leukemia (Metzker, 2010). Recently, Link and colleagues performed whole-genome sequencing on AML leukemic cells from a 37 year old woman with suspected cancer susceptibility syndrome (Link et al., 2011). The patient developed a therapy-related acute myeloid leukemia (t-AML) after chemotherapy for her breast cancer and ovarian cancer. Whole-genome sequencing revealed a novel, heterozygous 3-kilobase deletion removing exons 7-9 of *TP53* gene in germline DNA of patient normal skin cells. The deletion became homozygous in the leukemia DNA as a result of uniparental disomic recombination. Additionally, a total of 28 somatic single-nucleotide variations in coding regions, 8 somatic structural variants, and 12 somatic copy number alterations were identified in the patient's leukemia genome. Using a similar approach, Welch and colleagues performed whole-genome sequencing on a 39-year-old woman with a diagnosis of acute promyelocytic leukemia (APL) with unusual genetic lesion (Welch et al., 2011). The sequencing identified a novel cryptic insertion of *PML* gene into chromosome 17 that produced a classic pathogenic *PML/RARA* gene fusion figure 1B. This type of genetic event could not have been identified with routine cytogenetic and FISH techniques. The results led to a change in therapy using a less toxic targeted reagent, retinoic acid, rather than using the high risk procedure of allogeneic bone marrow transplantation.

These two cases represent excellent examples that whole-genome sequencing in leukemia not only detects novel genetic mutations in a cancer genome, but also directly benefits patient care. Although next generation sequencing has not been used for routine clinical diagnosis due to its high cost and long turnaround time (7 weeks in the latter case), it does provide insights for understanding the molecular mechanisms of leukemogenesis at the DNA sequence level in individual patients. Most likely, it will be used in clinical diagnosis with a "one-size-fits-all" feature in the near future.

#### 4. Epigenetics

The completion of the human genome in 2003 held great promise for uncovering the cancer-causing genetic mutations that would allow for the development of targeted therapies and the eradication of cancer. Unfortunately, this has not come to fruition due, in large part, to the role of epigenetic modifications in the development of cancer. An individual's epigenetic makeup is much more complex than their genetic makeup. Human DNA sequence in all somatic tissue cells (except lymphocytes) is identical in a given individual. However, epigenetics presents in a developmental and tissue-specific manner. Epigenetic modifications are largely responsible for the differences in all somatic tissue cells such as brain, liver, skin

cells, hair cells and the cells that make up the human eye. As a matter of fact, epigenetic modifications are responsible for regulating the expression of genes that establish each of the tissue types in the body.

Epigenetics is defined as the change of gene expression caused other than DNA sequence change (Bird, 1980; Robertson & Jones, 2000). There are 3 key epigenetic players which work in concert to control/alter gene expression. These include DNA methylation, histone modifications and non-coding RNAs inference (Figure 2). DNA cytosine methylation occurs at the 5<sup>th</sup> position of cytosine in CpG dinucleotide. Methyl binding proteins are recruited to methylated DNA regions and can block transcription factors in the promoter of a gene. The inaccessibility of transcription factors to the DNA results in a silenced gene. There are also numerous histone modifications such as acetylation, methylation, phosphorylation, ubiquitylation and sumoylation which can be present alone or in combination and each has an impact on chromatin structure. For example, some histone modifications (histone code) are associated with open chromatin (euchromatin) and some are associated with condensed chromatin (heterochromatin). If the chromatin is open, genes are accessible and can be transcribed. Alternately if the chromatin is closed, the genes are inaccessible to transcription




Fig. 2. Epigenetic network. Cell epigenetic network consists of DNA methylation, histone methylations (pentagon), histone acetylation (triangle), chromatin (nucleosome) remodeling, and RNA interference (RNAi) induced by microRNAs and short interfering RNAs (siRNAs). Interaction between these epigenetic components results in transition of euchromatin to heterochromatin. The transcription is inactivated (silenced) permanently when the focal open chromatin becomes a closed heterochromatin configuration (Adapted from Wang MX and Shi HD: *Basics of Molecular Biology, Genetic Engineering and Metabolic Engineering*. In: Fu, PC, Latterich, M, and Panke, S (Eds): *Systems Biology and Synthetic Biology*, John Wiley & Sons, Inc., pp.36, 2009, with permission)

factors and therefore cannot be transcribed. Finally, non-coding RNAs play a role in gene expression by binding and degrading messenger RNA and inhibiting protein assembly (Chen J et al, 2010, Melo and Esteller, 2011). While each of these modifications plays an important role in gene expression, DNA methylation has been the most widely studied epigenetic modification that is associated with the development of acute leukemia and other types of cancer.

DNA methylation occurs globally in the normal genome and is estimated to affect between 70 and 80% of all CpG dinucleotides in human cells (Bird, 1980; Robertson & Jones, 2000). These dinucleotides are not uniformly distributed across the genome but occur in clusters such as large repetitive sequences or in CG-rich DNA stretches known as CpG islands (CGIs). Normally, the majority of the CpG dinucleotides which are found in intragenic regions, including repetitive sequences such as satellite sequences and centromeric repeats, contains methylated CpG dinucleotides; while CGIs which are found preferentially in the promoter regions of genes typically contain unmethylated CpG dinucleotide (Craig & Bickmore, 1994). Some exceptions to this rule include those CGIs located on the inactive X chromosome in females (Goto & Monk, 1998) and those associated with imprinted genes (genes for which only the paternally- or maternally-inherited allele is expressed) which are methylated in the normal state (Li et al., 1993; Razin & Cedar, 1994).

In leukemia, the normal pattern of methylation gets reversed. Those regions of the genome that are normally methylated (and inactivated) such as repetitive sequences lose methylation and result in genomic instability. Those regions of the genome which are typically unmethylated such as the promoters of tumor suppressor genes become methylated and gene expression is lost. A typical gene comprises a promoter region, transcriptional start site (TSS), 5' untranslated region (UTR), exons, introns and a 3'UTR. CGIs may encompass each of these genetic regions. Typically methylation present within the gene body (exons, introns) is associated with gene expression and methylation present in gene promoters, 5'UTRs and the first exon is associated with gene silencing. The majority of genome-wide methylation studies to date have focused on CGI at the promoter regions of genes via microarray methylation analysis. Recently, it has been suggested that not only are the CGI themselves important but that the flanking genomic regions termed CpG shores are more highly correlated with gene silencing (Irizarry et al., 2009).

## 5. Emerging epigenetic technologies

DNA methylation plays an important role in acute leukemia. This is evidenced by the growing number of studies that have recently been published describing methylation profiles for many types and subtypes of leukemia. A number of strategies have been used to examine DNA methylation and over time these methods have progressed from small-scale candidate gene analysis to the ability to construct whole-genome methylation profiles (Laird, 2010). These can broadly be divided into three classes: those that require bisulfite conversion, those that are affinity based and those that require the use of restriction enzymes. Restriction enzyme-based methods such as DMH (Huang et al., 1999) and MCA (Huang et al., 1999; Toyota & Issa, 2002) rely on methylation-sensitive enzymes and are limited by the fact that restriction sites are not present in all possible CpG rich regions of interest. In affinity based approaches such as methylated DNA immunoprecipitation (MeDIP) (Weber et al., 2005) and methylated CpG island recovery assay (MIRA) (Rauch &



Pfeifer, 2005), fragmented DNA is immunoprecipitated using a monoclonal antibody to 5-methylcytosine or by methylated DNA binding proteins respectively. Methylated DNA is enriched in affinity based methods, however, these methods are limited by the sensitivity of the antibody or protein being used and are typically biased towards regions of the genome with a high density of methylation. Sodium bisulfite converts unmethylated cytosines to uracils in DNA strands. Once the conversion has taken place the sequence can be determined after PCR because the cytosines that were originally unmethylated will be converted to thymines and those that are methylated will remain cytosines. The net effect of the conversion process is that the complexity of the genome is reduced from 4 bases to only 3 bases. Bias may be introduced due to incomplete bisulfite conversion, destruction of DNA strands and also by the efficiency of bisulfite PCR. After the samples are prepared, they can be hybridized to microarrays or used to make sequencing libraries for next generation sequencing. The recent development of high throughput technologies holds the promise of providing biological insight and new avenues for translational research and clinical applications.

### 5.1 Arrays

The extent of genome coverage is primarily determined by the resolution of the utilized microarray platform which has progressed rapidly from arrays that examine the DNA methylation present in select CGI to those that examine all CGIs and/or promoters and even to those that examine the entire genome (i.e. Agilent and Nimblegen). Microarray analysis is dependent upon the sample preparation used. Those that use restriction enzymes typically involve a co-hybridization of a test (i.e. leukemia) sample and a reference sample (i.e. bone-marrow cells from a healthy donor). Differential methylation is determined by comparing the intensity of the test sample to the intensity of the reference sample at each locus represented on the array. If the DNA is prepared using an affinity method, the reference sample is usually an aliquot of the original sample DNA while the test sample is the immunoprecipitated portion derived from the original sample. Methylated sequences are detected by comparing the fluorescence signal for each probe corresponding to known genomic sequences for reference and the test samples. The loci that are enriched in the test sample are potential methylation candidates. There are also arrays that require DNA to be bisulfite converted (i.e. Illumina). These arrays are also known as SNP chips and methylated cytosines are identified by the presence of a cytosine at a particular locus as opposed to a thymine. These later arrays give site-specific methylation profiles whereas the oligonucleotide microarrays give region specific methylation profiles.

### 5.2 Next Generation Sequencing (NGS)

Next generation sequencing has revolutionized the ability to perform genomic research since it was introduced in 2007 (Metzker, 2010 for a review). More recently, this technology has been adapted to epigenomic research including DNA methylation analyses. NGS technologies can generate millions of sequencing reads in parallel and has led to a dramatic increase in the number of genomic and epigenomic sequences encompassing normal and diseased tissues. There are multiple sequencing platforms available and the choice of platform and methodology is dependent on the scientific application and the capacity for extensive bioinformatics analysis.

Whole genome bisulfite sequencing (WGBS) provides coverage at a single base pair resolution and is the most comprehensive NGS technology in DNA methylation analysis. WGBS provides unbiased coverage of the genome allowing for interrogation of whole regions of the genome that are often missed by other methodologies. This method requires the most extensive bioinformatics and is the most expensive because more sequences are required to cover the entire genome. Therefore, this option may not be suitable for laboratories without bioinformatics support or with a small budget.

Reduced representation bisulfite sequencing (RRBS) is a less expensive alternative to WGBS. As the name of the method implies, the genome is reduced in size using an enzyme which enriches for regions of the genome that contain CpG dinucleotides. To be more specific, coverage includes approximately 12% of all CpG dinucleotides and 84% of all CpG islands in the human genome (Smith et al., 2009). In total, about 1% of the genome is covered which greatly reduces the cost of sequencing and the resources needed for alignments while providing data for those regions of the genome that are enriched for CpG dinucleotides. RRBS is an excellent alternative to WGBS with the caveat that important genomic regions that are not enriched for CpG dinucleotides are not assayed. As an example of the consequence of this limitation, it was recently published that much of the methylation present in colon cancer occurred in CGI shores and that this methylation was highly correlated with gene expression (Irizarry et al., 2009). RRBS covers less than 50% of the CGI shores so in this particular region of the genome, important data may be lost (Gu et al., 2011). RRBS may become an optional platform for targeted DNA methylation analysis for clinical diagnostic purposes.

Affinity sequencing utilizes either an antibody against 5-methylcytosine or proteins with methyl binding domains to immunoprecipitate (or enrich for) methylated DNA. This method does not require bisulfite conversion and produces sequences for regions of the genome that are methylated. However, it does not provide data for the methylation status of individual CpG dinucleotides. Bioinformatics analysis requires genome alignment and must take into account the density of CpG dinucleotides in a given region because the efficiency of anti-5' methylcytosine and methyl binding proteins is dependent on the number of methylated cytosines in a given region (Weber et al., 2005).

## **6. DNA methylation in acute leukemia**

DNA methylation is an important epigenetic mechanism to control gene expression. In many cases, tumor suppressor genes (TSGs) are inactivated by somatic mutations (point mutations or deletions) as the "first hit", DNA methylation silences the gene expression of other allele as the "second hit", or in a reversed sequence. In this regards, aberrant DNA methylation plays a crucial role in leukemogenesis (Herman & Baylin, 2003; Galm et al., 2006). Using various technologies described above, many aberrant DNA methylation loci have been identified in both ALL and AML

### **6.1 DNA methylation in ALL**

Genomic DNA methylation profile in a given cell is defined as methylome. There are numerous recurrent chromosomal and genetic abnormalities in ALL. However, these abnormalities are neither sufficient nor necessary in the development of ALL. Therefore it is

likely that epigenetic modifications also contribute to the leukemogenesis in ALL. Numerous studies have been published that have focused on a single candidate gene or groups of genes involved in important cellular processes such as cell signaling pathways, apoptosis, regulation of transcription and cell cycle control in pediatric ALL (Agirre et al., 2006; Canalli et al., 2005; Cheng et al., 2006; Corn et al., 1999; Garcia-Manero et al., 2003; Gutierrez et al., 2003; Iravani et al., 1997; Paixao et al., 2006; Roman-Gomez et al., 2002; Roman-Gomez et al., 2004; Roman-Gomez et al., 2006, 2007; Sahu & Das, 2005; Scholz et al., 2005; Stam et al., 2006; Tsellou et al., 2005; Yang et al., 2006; Zheng et al., 2004), and adult ALL (Batova et al., 1997; Chim et al., 2001; Garcia-Manero et al., 2002a; Garcia-Manero et al., 2002b; Hutter et al., 2011; Jimenez-Velasco et al., 2005; Martin et al., 2008; Roman et al., 2001; Roman-Gomez et al., 2004; Scott et al., 2004; Shteper et al., 2001; Taniguchi et al., 2008; Yang et al., 2006). A search of PubMeth ([www.pubmeth.org](http://www.pubmeth.org)) provides a list of 46 methylated genes that have been associated with acute lymphoblastic leukemia including *ABCB1*, *ABL1*, *ADAMTS1*, *ADAMTS5*, *AHR*, *APAF1*, *BNIP3*, *CDH1*, *CDH13*, *CDKN1A*, *CDKN1C*, *CDKN2A*, *CDKN2B*, *CHFR*, *DAPK1*, *DIABLO*, *DKK3*, *ESR1*, *EXT1*, *FHIT*, *HCK*, *KLK10*, *LATS1*, *LATS2*, *LMNA*, *MGMT*, *MME*, *MYOD1*, *NNAT*, *NR0B2*, *PARK2*, *PGR*, *PPP1R13B*, *PTEN*, *PYCARD*, *RARB*, *SFRP1*, *SFRP2*, *SFRP4*, *SFRP5*, *SYK*, *THBS1*, *THBS2*, *TP73*, *WIF1* and *WRN*.

Recent studies have increased our knowledge of aberrantly methylated loci in ALL by utilizing genome-wide technologies to construct genome-scale methylomes. These studies have shown that methylation profiles can be used in diagnosis (Davidsson et al., 2009; Dunwell et al., 2010; Milani et al., 2010; Stumpel et al., 2009; Taylor et al., 2007a; Taylor et al., 2007b; Vilas-Zornoza et al., 2011), prognosis (Davidsson et al., 2009; Hogan et al., 2011; Kuang et al., 2008; Milani et al., 2010), and in the treatment (Hogan et al., 2011; Vilas-Zornoza et al., 2011) of individuals with ALL.

As an example of the breadth and depth provided by using genome-scale technologies, Davidsson and colleagues used bacterial artificial chromosome arrays and genome-wide methylation arrays in two of the most common subtypes of pediatric ALL, t(12;21)(p13;q22) and high hyperdiploidy (Davidsson et al., 2009). The methylation microarray used covers all of the UCSC-annotated CGI and promoter regions of all RefSeq genes and contains a total of 385,000 probes. A total of 8,662 genes were identified with significant methylation present within the promoter and the 10 individuals with hyperdiploid ALL had approximately twice as many hypermethylated genes as the 10 individuals with the t(12;21) abnormality. Of particular importance is that none of the 30 genes with the highest methylation peaks in the ALL patients have previously been shown to be methylated in ALL or any other neoplasia. An additional study by Hogan and colleagues (Hogan et al., 2011) used the Infinium Human Methylation27 BeadChip to create methylation profiles for paired diagnostic/relapse samples from 33 pediatric ALL patients. This study identified over 900 genes that were preferentially methylated in relapse samples when compared to samples at diagnosis. Further combinatorial expression and copy number variation analysis identified important biological pathways such as the WNT/beta-catenin pathway and the MAPK pathway which may be implicated in the relapse of pediatric ALL.

## 6.2 DNA methylation in AML

Like in the case of ALL, numerous studies have been published using single-gene based methods such as methylation-specific PCR (MSP), combined bisulfite restriction analysis

(COBRA) or array to identify a single or a group of genes with abnormal DNA methylations in AML. The examples include *CDH1*, *ESR1*, *IGSF4*, *FHIT*, *p15INK4B*, *p21CIP1/WAF1*, *MEG3*, *SNRPN*, *p73*, *SOCS1*, *CALC1*, *HIC-1*, *CTNNA1*, *CEBPA*, *MLH1*, *MGMT*, *CNAML*, *HOXA1*, *MYOD*, *KRT13*, *NR2F2*, *PITX2*, *RBP1*, *CEBPA*, *BAHCC1*, *EVII*, and *DAPK* genes (Ekmekci et al., 2004; Agrawal et al., 2007; Desmond et al., 2007; Glasow et al., 2008; Rosu-Myles & Wolff, 2008; Melnick, 2010; Oki & Issa, 2010; Lugthart et al., 2011; Lin et al., 2011). Often hypermethylation in these gene CpG-island-promoters results in transcriptional silencing and loss of the function in important biological pathways (Calvanese et al, 2011).

High throughput technologies such as mass spectrometry, microarray and next generation sequencing (NGS) have been used to study altered DNA methylation at the genome-wide scale. Bullinger and colleagues used a combination of base-specific cleavage biochemistry and mass spectrometry (MALDI-TOF-MS) to quantify DNA methylation in 92 selected genomic regions of 256 AML patient samples (Bullinger et al., 2010). Distinct DNA methylation patterns were identified in abnormal cytogenetic subgroups and the DNA methylation levels (CpG units) could provide independent prognostic information. Alvarez and colleagues used a bead array-based methylation assay to examine the methylation status of 1,505 CpG-sites from 807 genes on 116 de novo AML patients (Alvarez et al., 2010). They confirmed that the DNA methylation signatures were associated with the specific cytogenetic status. In addition, aberrant DNA methylation of the promoter of *DBC1* could predict the disease-free and overall survival time in normal karyotype cases. Interestingly, the aberrant DNA methylation pattern could be induced by genetic transduction of *MLL* rearrangement fusion genes in normal human hematopoietic stem/progenitor cells (HSPC), but cannot be induced by *AML1/ETO* or *CBFβ/MYH11* fusion gene. This is the direct evidence of interaction between genetic and epigenetic alteration in AML. Using the same platform, Wilop and colleagues found a gain of overall methylation in 32 AML patient samples (Wilop et al., 2011). The methylation pattern was maintained at relapse with increased density and extended to additional genes, consistent with the previous studies (Agrawal et al., 2007; Kroeger et al., 2008). These observations provided a strong scientific basis for DNA methylation to be used as a biomarker for diagnosis, minimal residual disease detection and clinical follow-up in AML patients.

A more comprehensive study was conducted by Figueroa and colleagues using HpaII tiny fragment enrichment by ligation-mediated PCR (HELP), linked with a microarray platform measuring the methylation abundance of 50,000 cytosines distributed among 14,000 gene promoters in 344 AML patient samples (Figueroa et al., 2010). Based on the DNA methylation signatures, these patients could be classified into 16 epigenetically unique subtypes. Although the DNA methylation patterns were different among subtypes, none of the AML subtypes were similar to any of the stages of normal myeloid maturation indicating a distinct difference between leukemia and normal myeloid cell methylomes. Furthermore, they found a set of 45 genes to be aberrantly methylated common in all AML cases, but not in normal myeloid cells. Patients with a *CEPBA* signature have markedly poor clinical outcomes. Functionally, the hypermethylated genes were down-regulated and associated with biologically relevant pathways in leukemogenesis. These genes include zinc finger transcription factors, components in retinoic acid, STAT, p53 signal pathways, DNA-damage repair, immune response and tumor suppressors (Sternberg et al, 2004). It is anticipated that a complete AML methylome with single base pair resolution by next generation sequencing such as whole genome bisulfite sequencing (WGBS) will be published soon.



## 7. Interaction between genome and epigenome in leukemia

Data from cytogenetic karyotyping, conventional sequencing, microarray and whole genome sequencing indicates that there are extensive and distinct genetic and epigenetic alterations in acute leukemia genomes. Recent studies showed that genetic and epigenetic alterations are not independent events. Specific DNA methylation patterns are identified in specific cytogenetic subgroups of ALL (Davidsson et al., 2009) and AML (Figueroa et al., 2010). Chromosomal translocations result in fusion oncoproteins that can recruit components for DNA methylation, histone deacetylation and transcriptional repressor complexes (Croce LD, 2005; Chen et al., 2010). In contrast, DNA hypomethylation may lead to abnormal microRNA expression and chromosomal instability that in turn may result in chromosomal translocations (Eden et al. 2003; Calvanese et al, 2010; Popp & Bohlander et al., 2010; Toyota et al. 2010; Melo and Esteller, 2011).

AML with t(8;21)(q22;q22) translocation results in the fusion genes of *RUNX1-RUNX1T* (or *AML1- ETO*). The oncoprotein represses the transcription of wild-type *AML1* target genes by recruiting co-repressor complexes (Ferrara & Del Vecchio, 2002). *AML1* (also known as *RUNX1* or *CBFA*) is a transcription factor containing the DNA binding domain of the  $\alpha$ -subunit of core binding factor (CBF). Another subtype of AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22) results in *CBFB-MYH11* fusion gene that contains a  $\beta$  subunit of CBF. Together,  $\alpha$ -subunit and  $\beta$  subunit forms a heterodimeric core binding transcription factor and plays an important role in normal hematopoiesis and myeloid differentiation (Link et al., 2010). However, fusion forms of these truncated subunits lost the ability to form core binding factor and no longer induce myeloid differentiation (Paschka, 2008). Even more, the fusion proteins actively repress the transcription of normal *AML1* target genes by either recruiting histone deacetylase (HDAC) or DNA methyltransferase 1 (DNMT1) or by cooperating nuclear receptor co-repressor 1 (NCOR1), NCOR2 and SIN3A15 to form a repressor complex (Liu et al., 2005). As a result, normal myeloid differentiation mediated by CBF is disrupted and hematopoietic stem cells (HSCs) and myeloid progenitor cells cannot achieve the next mature stages, and result in accumulation of leukemia blasts in bone marrow and blood. Since AML with t(8;21) and inv(16) or t(16;16) are involved in a common pathway at the molecular level and show specific clinical features, these two genetic subtypes are called core binding factor leukemia (Ferrara & Del Vecchio, 2002). This leukemia responds well to high doses of cytarabine (HiDAC) and has a better prognosis (Dombret et al., 2009; Solis, 2011).

Acute promyelocytic leukemia (APL) is another example in which blockage of myeloid differentiation by the fusion oncoproteins is mediated by an interaction between genetic and epigenetic mechanisms. All patients with APL have the t(15;17) translocation or one of its variants t(11;17), t(5;17) (Warrell et al., 1993). Translocation t(15;17) results in a fusion protein PML-RARA typically comprised of variable portions of PML protein and all but the first 30 amino acids of retinoic acid receptor- $\alpha$  (RARA). Wild-type RARA protein is a transcriptional activator crucial for normal hematopoiesis and myeloid differentiation. Many RARA target genes including specific transcription factors such as *PU.1* (*SPI1*) and *C/EBP $\beta$*  (*CEBPB*) have been identified to have RARA binding sites. The fusion protein PML-RARA functions as a transcriptional repressor, but not an activator, by binding to promoter region of RARA target genes and recruiting proteins including HDAC, NCOR1 and NCOR2



(N-CoR) complex, DNMT1, DNMT3A, repressive histone methyltransferases and polycomb group proteins (Licht et al., 2006). DNA methyltransferases (DNMT1 and DNMT3A) induce DNA methylation. Histone deacetylase (HDAC) removes acetyl group from histones. Together with other repressive proteins, the focal chromatin structure at the promoter regions of target genes are converted to a closed configuration and the transcription initiation is abolished. Promyelocytes of APL lack key transcription factors for further maturation. Accumulation of abnormal promyelocytes in bone marrow is a diagnostic feature of APL. A high dose of all-trans-retinoic acid (ATRA) relieves this repression by allowing the release of the N-CoR complex and the recruitment of a co-activator complex and it has become the cornerstone in treatment of APL by molecular targeting (Wang & Chen, 2008).

## 8. Molecular mechanisms of leukemogenesis

Among more than 100 types of cancer with different tissue origins, acute leukemia is a unique form that is originated from hematopoietic stem cells (HSC) or hematopoietic progenitor cells in bone marrow. In order to acquire a malignant phenotype, leukemic cells must have all the malignant biological properties including self-sufficiency in growth signals, insensitivity to growth-inhibitory signals, altered cellular metabolism, evasion of programmed cell death (apoptosis) and immunological destruction, limitless replicative proliferation and tissue invasion and metastasis (Hanahan & Weinberg, 2000; 2011). At the molecular level, the phenotype of leukemic cells represents a global change of gene expression due to irreversible genetic and epigenetic alterations. These changes affect biological pathways of cell differentiation, cell cycle regulation, tumor suppression, drug responsiveness, and apoptosis. Identification of the molecular signature of leukemia as well as the genetic background of the host individual will provide a unique biological road map for each patient that will become the foundation for personalized therapy in the future (Godley et al., 2011).

The etiology of acute leukemia is not completely clear. Some environmental risk factors for ALL including parental occupation, parental tobacco or alcohol use, prenatal vitamin use, diet, exposure to pesticides or solvents, infectious pathogens and exposure to ionizing radiation or the highest levels of residential power-frequency magnetic fields have been reported (Belson et al., 2007; Milne et al., 2010; Bailey et al., 2011). Environmental risk factors for AML include exposure to ionizing radiation and benzene (Bowen, 2006; Smith et al., 2011). The cytotoxic chemotherapy (alkylating agents and topoisomerase-II inhibitors) and/or radiotherapy for other solid tumors and pre-leukemic conditions myelodysplastic syndromes in the elderly are proven risk factors for AML (Löwenberg et al., 1999; Garcia-Manero et al., 2011).

ALL occurs exclusively in childhood although adult ALL exists. Screening of neonatal cord-blood samples has revealed several specific leukemic chromosomal translocations. One particular clone with the *TEL-AML1* fusion gene derived from chromosomal translocation  $t(12;21)(p13;q22)$  is found in 1% of newborn babies. The prevalence of B-ALL with this fusion gene is 100 times higher than those who do not have the fusion gene (Cobaleda et al., 2009; Lausten-Thomsen et al., 2011). Similarly, some leukemic translocations such as  $t(8;21)(q22;q22)$  resulting in *AML1-ETO* fusion gene can be detected in neonatal blood

samples from the teenagers diagnosed with AML (Mori et al., 2002). In addition, ALL and AML occurs in approximately 10% of identical twins with these or other karyotypes (Mori et al., 2002; Greaves et al., 2003). These observations support the hypothesis that these specific genetic alterations at the fetal stage increases the frequency of ALL and AML, but additional postnatal events, either genetic or epigenetic, are required for full leukemic transformation (Greaves & Wiemels, 2003; McHale et al., 2004; Wiemels et al., 2009).

Recent studies suggest that the original leukemic clone is most likely raised from hematopoietic stem cells (HSC) or lineage committed precursor cells (Clarke et al. 1987; Lapidot et al., 1994; Cox et al., 2004, 2007; Jamieson et al., 2004). Under the influence of genetic and the environmental risk factors described above, normal HSC or precursor cells undergo malignant transformation and become leukemia stem cells (LSCs) (Passegué et al., 2003). LSCs have the distinct properties with partial normal HSC and partial leukemia cell features. These cells are characterized by self-renewal, over proliferation and the capacity to develop an entire leukemic blast population (Huntly & Gilliland, 2005; Becker & Jordan, 2010). Identification of LSCs by specific biomarkers and development of specific agents to target LSCs has significant clinical implication since eradication of LSCs will prevent the relapse and cure the leukemia (Jan et al., 2011).

At the molecular level, based on the facts that chromosomal translocations and point mutations can be found in the majority of AML patients, Kelly and colleagues suggested a two-hit model that AML leukemogenesis driven by two types of gene mutations (Kelly et al., 2002). The class 1 mutations result in constitutive activation of cell-surface receptors, such as receptor tyrosine kinases, FLT3 and KIT. Through various downstream signaling pathways, constitutive activation confers proliferation and survival advantage leading to clonal expansion of the affected hematopoietic stem cell or progenitors. The class 2 mutations, exemplified by formation of fusion genes from the t(8;21) or inv(16) chromosomal translocations or overexpression of HOX genes, block myeloid differentiation. Either class 1 or class 2 lesions alone does not cause leukemia in mouse models (Downing, 2003). AML develops only when both classes of lesions are present.

This model, however, provides a less cogent explanation for AML derived from myelodysplastic syndrome and therapy-related AML (t-AML) in elderly. These AML are frequently associated with chromosomal deletion or addition (Godley & Larson, 2008). Furthermore, this model also does not fully explain the AML containing normal karyotype with multiple point mutations in *FLIT3*, *NPM1*, and *CEBPA* genes (Foran, 2010). The class 1 mutations in ALL have not fully established. Epigenetic factors, especially DNA hypermethylation that can inactivate various putative tumor suppressor genes, DNA-repair, cell cycle, apoptosis related genes appear to play important roles in leukemogenesis (Issa et al., 1997; Esteller, 2008; Kulis & Esteller, 2010; Deaton & Bird, 2011). An integrated model combining genetic and epigenetic factors at the individual, cellular and molecular levels for acute leukemia is proposed (Figure 3).

## 9. Clinical applications

Genetic and epigenetic studies from basic science have been applied to many aspects in the clinical management of acute leukemia patients. The current WHO classification of tumors of hematopoietic and lymphoid tissues has included an increasing number of clinicopathologic entities defined by chromosomal abnormalities as well as gene mutations.




Fig. 3. A new model of leukemogenesis integrated genetic and epigenetic mechanisms and their clinical implications. Although the inherited factors in leukemogenesis of acute leukemia is not apparent, the genetic alterations including chromosomal translocations and numerical changes such as trisomy 21 have been found at prenatal stage. The changes may be related to maternal factors such as carcinogens exposure, nutrients (including folate) and aging in pregnancy. The incidence of acute leukemia is dramatically increased (~100 times higher), but not all children will have the leukemia when carrying the specific chromosomal abnormalities at the prenatal stage. It indicates the second hit, either genetic mutations or epigenetic alterations, is required for a full leukemic transformation. With an interaction between genetic and epigenetic networks, the gene expression profile is globally changed in hematopoietic stem cells or precursors. Corresponding functional changes including cell signalings and cell cycle control result in a malignant leukemia phenotype. These leukemia cells escape from immune surveillance and accumulate in bone marrow and blood, thus acute leukemia is developed. Clinically, genetic abnormalities have been used as biomarker for disease classification and diagnosis, while aberrant epigenetic alterations have become therapeutic targets. Note: HSC: hematopoietic stem cell; TSG: tumor suppressor gene; DNMTI; HDACI; RNAi; Epigenetic network: DNA methylation, histone modifications and microRNA. siRNAs. +: increase; -: decrease; x: disruption.

These subtypes of AML or ALL often have a distinct morphology, immunophenotype and clinical course. Some of these patients with specific genetic or epigenetic alterations may respond to specific chemotherapeutic reagents or epigenetic modifiers. Mutation status of *NPM1*, *CEBPA* and *FLT3* genes has been used in risk assessment, prognostic evaluation and guidance of therapy (Foran, 2010). Detection of specific fusion RNA levels using quantitative RT-PCR molecular tests in patient blood has been used routinely for therapeutic monitoring and minimal residual disease detection (Gulley et al., 2010).

Because of the genetic heterogeneity and the limited number of meaningful genetic biomarkers identified in acute leukemia, the use of aberrant epigenetic alterations, especially DNA methylation and microRNA as biomarkers, is being studied at the single gene as well as genome-wide level. Agrawal and colleagues reported that the methylation of *ERa* and *p15INK4B* genes occurred frequently and specifically in acute leukemia but not in healthy controls or in nonmalignant hematologic diseases (Agrawal et al., 2007). Aberrant DNA methylation of these two genes was detectable in >20% of leukemia patients during clinical remission. The presence of detectable methylation was correlated to minimal residual disease (MRD) and associated with subsequent relapse (Agrawal et al., 2007). Wang and colleagues demonstrated that the aberrant DNA methylation of *DLC-1*, *PCDHGA12* and *RPIB9* genes can be identified in over 80% of ALL patients (Wang et al., 2010). Using a single gene *DLC-1*, we could trace clinical B-ALL cases up to 10 years retrospectively and the *DLC-1* methylation is correlated with patient clinical status. Importantly, these specific DNA methylation loci are retained in leukemia cells and can be detected in relapse. Compared with primary leukemia at diagnosis, relapsed leukemia maintains the original methylation loci, yet extends methylation in addition genes (Kroeger et al., 2008; Figueroa et al., 2010). These studies indicated that the DNA methylation is a biologically stable marker that can be used for MRD detection and patient follow up in acute leukemia.

In terms of therapy, there are two groups of epigenetic agents currently in clinical use, DNA methyltransferase inhibitor (DNMTI) and histone deacetylase inhibitor (HDACI) (Peters & Schwaller, 2011). The prototypic nucleoside analogue DNMT inhibitors include 5-azacytidine (5-Aza or azacitidine) and 5-aza-2'-deoxycytidine (decitabine). They exert a demethylating effect by incorporating into DNA (5-Aza is also incorporated into RNA) and form a covalent complex with the DNMT enzymes. The enzymes are trapped and eventually degraded and the newly synthesized DNA strand will not be methylated (Schoofs & Müller-Tidow, 2011). These two agents are active in a broad range of myeloid neoplasms including AML and myelodysplastic syndrome (MDS). Because of its excellent efficacy (~50% response rate) in clinical trials, both agents have been approved by the US FDA for the treatment of MDS (Silverman & Mufti, 2005). The use of these reagents in treatment of AML has been actively investigated and showed promising utility especially in elderly patients (Musolino, 2010). The second group of epigenetic therapeutic agents is histone deacetylase inhibitor (HDACI). This group consists of heterogenic compounds that may reactivate the genes that have been turned off by histone deacetylation. Particularly, HDACI has demonstrated some efficacy in treat of core binding factor (CBF) leukemia. Clinical trials have been conducted using HDACI alone or in combination with DNMTI in CBF and other subtypes of leukemia patients (Quintás-Cardama et al., 2011).

## 10. Conclusion

Acute leukemia (ALL and AML), like all other cancer types, is a genetic disease. DNA sequence examination in the specific loci as well as at the genome-wide level has confirmed this original hypothesis. Epigenetic alterations including DNA methylation, histone modifications and microRNA play a functional role in leukemogenesis. Interaction between genetic and epigenetic elements changes the global landscape of gene expression, protein synthesis and metabolism in hematopoietic stem cells and/or committed precursor cells which results in leukemic transformation. Systemic study at the genome level in DNA sequence and DNA methylation, gene and microRNA expression profile, proteome and metabolism not only provides the insight for understanding leukemogenesis, but also identifies biomarkers for leukemia stem cell, leukemia classification, diagnosis, risk assessment, therapy selection, response prediction, prognosis, minimal residual disease detection and other aspects of clinical decision-making and applications. Toward this end, current advanced high throughput technologies including next generation sequencing, microarray, proteomics, targeted molecular testing and bioinformatics have provided powerful tools. Well-designed clinical trials will make a clinical connection with new scientific discoveries in leukemia genome and epigenome. Assembly and synthesis of the massive amounts of new information by systems biology will generate a high resolution picture of leukemogenesis of acute leukemia. With combined efforts from bench and bedside, the ultimate goal is to eradicate all leukemic blasts including leukemic stem cells in the patients by less toxic reagents to completely cure leukemia in the future.

## 11. Acknowledgments

We thank Ms. Marie Schultz for her editorial assistance.



## 12. References

- Agirre, X., Roman-Gomez, J., Vazquez, I., Jimenez-Velasco, A., Garate, L., Montiel-Duarte, C., Artieda, P., Cordeu, L., Lahortiga, I., Calasanz, M. J., Heiniger, A., Torres, A., Minna, J. D., & Prosper, F. (2006). Abnormal methylation of the common PARK2 and PACRG promoter is associated with downregulation of gene expression in acute lymphoblastic leukemia and chronic myeloid leukemia. *Int.J.Cancer*, Vol.118, No.8, pp. 1945-1953.
- Agrawal S, Unterberg M, Koschmieder S, zur Stadt U et al (2007). DNA methylation of tumor suppressor genes in clinical remission predicts the relapse risk in acute myeloid leukemia. *Cancer Res*. Vol. 67, No.3, pp.1370-1377.
- Alvarez S, Suela J, Valencia A, Fernández A et al. (2010). DNA methylation profiles and their relationship with cytogenetic status in adult acute myeloid leukemia. *PLoS One*. Vol.5, No.8, pp. e12197.
- Bailey HD, Armstrong BK, de Klerk NH, Fritschi L, Attia J, Scott RJ, Smibert E, Milne E; Aus-ALL Consortium. (2011). Exposure to professional pest control treatments and the risk of childhood acute lymphoblastic leukemia. *Int J Cancer*. Vol.129, No.7, pp.1678-188.
- Bassan R & Hoelzer D. Modern therapy of acute lymphoblastic leukemia. *J Clin Oncol*. Vol.29, No.5, pp.532-543.
- Batova, A., Diccianni, M. B., Yu, J. C., Nobori, T., Link, M. P., Pullen, J., & Yu, A. L. (1997). Frequent and selective methylation of p15 and deletion of both p15 and p16 in T-cell acute lymphoblastic leukemia. *Cancer Res.*, Vol.57, No.5, pp. 832-836.
- Becker MW & Jordan CT. (2011). Leukemia stem cells in 2010: current understanding and future directions. *Blood Rev*. Vol.25, No.2, pp.75-81.
- Bell O, Tiwari VK, Thomä NH, Schübeler D. (2011). Determinants and dynamics of genome accessibility. *Nat Rev Genet*. Vol.12, No.8, pp.554-564.
- Belson M, Kingsley B, Holmes A. (2007). Risk factors for acute leukemia in children: a review. *Environ Health Perspect*. Vol.115, No.1, pp.138-145.
- Bird, A. P. (1980). DNA methylation and the frequency of CpG in animal DNA. *Nucleic Acids Res*, Vol.8, No.7, pp.1499-1504.
- Boehm JS & Hahn WC. (2011). Towards systematic functional characterization of cancer genomes. *Nat Rev Genet*. Vol.12, No.7, pp.487-498.
- Bowen DT. (2006). Etiology of acute myeloid leukemia in the elderly. *Semin Hematol*. Vol.43, No.2, pp.82-88.
- Bullinger L, Ehrich M, Döhner K, Schlenk RF, Döhner H, Nelson MR, van den Boom D. (2010). Quantitative DNA methylation predicts survival in adult acute myeloid leukemia. *Blood*. Vol.115, No.3, pp.636-642.
- Burnett A, Wetzler M, Löwenberg B. (2011). Therapeutic advances in acute myeloid leukemia. *J Clin Oncol*. Vol.29, No.5, pp.487-494.
- Calvanese V, Fernández AF, Urdinguio RG, Suárez-Alvarez B et al. (2011). A promoter DNA demethylation landscape of human hematopoietic differentiation. *Nucleic Acids Res*. 2011 Sep 12.
- Canalli, A. A., Yang, H., Jeha, S., Hoshino, K., Sanchez-Gonzalez, B., Brandt, M., Pierce, S., Kantarjian, H., Issa, J. P., & Garcia-Manero, G. (2005). Aberrant DNA methylation

- of a cell cycle regulatory pathway composed of P73, P15 and P57KIP2 is a rare event in children with acute lymphocytic leukemia. *Leuk.Res.*, Vol.29, No.8, pp. 881-885.
- Chen J, Odenike O, Rowley JD. (2010). Leukaemogenesis: more than mutant genes. *Nat Rev Cancer*. Vol.10, No.1, pp.23-36.
- Cheng, Q., Cheng, C., Crews, K. R., Ribeiro, R. C., Pui, C. H., Relling, M. V., & Evans, W. E. (2006). Epigenetic regulation of human gamma-glutamyl hydrolase activity in acute lymphoblastic leukemia cells. *Am.J.Hum.Genet.*, Vol.79, No.2, pp. 264-274.
- Chim, C. S., Tam, C. Y., Liang, R., & Kwong, Y. L. (2001). Methylation of p15 and p16 genes in adult acute leukemia: lack of prognostic significance. *Cancer*, Vol.91, No.12, pp. 2222-2229.
- Clarke BJ, Liao SK, Leeds C, Soamboonsrup P, Neame PB. (1987). Distribution of a hematopoietic-specific differentiation antigen of K562 cells in the human myeloid and lymphoid cell lineages. *Cancer Res*. Vol.47, No.16, pp.4254-4259.
- Cobaleda C & Sánchez-García I. (2009). B-cell acute lymphoblastic leukaemia: towards understanding its cellular origin. *Bioessays*. Vol.31, No.6, pp.600-609.
- Corn, P. G., Kuerbitz, S. J., van Noesel, M. M., Esteller, M., Compitello, N., Baylin, S. B., & Herman, J. G. (1999). Transcriptional silencing of the p73 gene in acute lymphoblastic leukemia and Burkitt's lymphoma is associated with 5' CpG island methylation. *Cancer Res.*, Vol.59, No.14, pp.3352-3356.
- Cox CV, Evely RS, Oakhill A, Pamphilon DH, Goulden NJ, Blair A. (2004). Characterization of acute lymphoblastic leukemia progenitor cells. *Blood*. Vol.104, pp.2919-2925.
- Cox CV, Martin HM, Kearns PR, Virgo P, Evely RS, Blair A. (2007). Characterization of a progenitor cell population in childhood T-cell acute lymphoblastic leukemia. *Blood*. Vol.109, pp.674-682.
- Craig, J. M. & Bickmore, W. A. (1994). The distribution of CpG islands in mammalian chromosomes. *Nat Genet*, Vol.7, No.3, pp. 376-382.
- Davidsson, J., Lilljebjorn, H., Andersson, A., Veerla, S., Heldrup, J., Behrendtz, M., Fioretos, T., & Johansson, B. (2009). The DNA methylome of pediatric acute lymphoblastic leukemia. *Hum.Mol.Genet.*, Vol.18, No.21, pp.4054-4065.
- Deaton AM & Bird A. (2011). CpG islands and the regulation of transcription. *Genes Dev*. Vol.25, No.10, pp.1010-1022.
- Desmond JC, Raynaud S, Tung E, Hofmann WK, Haferlach T, Koeffler HP. (2007). Discovery of epigenetically silenced genes in acute myeloid leukemias. *Leukemia*. Vol.21, No.5, pp.1026-1034.
- Di Croce L. (2005). Chromatin modifying activity of leukaemia associated fusion proteins. *Hum Mol Genet*. Vol.14 Spec No 1:R77-84.
- Döhner H, Estey EH, Amadori S, Appelbaum FR, Büchner T, Burnett AK, Dombret H, Fenaux P, Grimwade D, Larson RA, Lo-Coco F, Naoe T, Niederwieser D, Ossenkoppele GJ, Sanz MA, Sierra J, Tallman MS, Löwenberg B, Bloomfield CD; European LeukemiaNet. (2010). Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. *Blood*. Vol.115, No.3, pp.453-474.

- Dombret H, Preudhomme C, Boissel N. (2009). Core binding factor acute myeloid leukemia (CBF-AML): is high-dose Ara-C (HDAC) consolidation as effective as you think? *Curr Opin Hematol.* Vol.16, No.2, pp92-97.
- Downing JR. (2003). The core-binding factor leukemias: lessons learned from murine models. *Curr Opin Genet Dev.* Vol.13, pp.48-54.
- Dunwell, T., Hesson, L., Rauch, T. A., Wang, L., Clark, R. E., Dallol, A., Gentle, D., Catchpoole, D., Maher, E. R., Pfeifer, G. P., & Latif, F. (2010). A genome-wide screen identifies frequently methylated genes in haematological and epithelial cancers. *Mol.Cancer*, Vol.9, pp.44.
- Eden A, Gaudet F, Waghmare A, Jaenisch R. (2003). Chromosomal instability and tumors promoted by DNA hypomethylation. *Science.* Vol.300, No.5618, pp.455.
- Ekmekci CG, Gutiérrez MI, Siraj AK, Ozbek U, Bhatia K. (2004). Aberrant methylation of multiple tumor suppressor genes in acute myeloid leukemia. *Am J Hematol.* Vol.77, No.3, pp.233-340.
- Esteller M. (2008). Epigenetics in cancer. *N Engl J Med.* Vol.358, No.11, pp.1148-1159.
- Estey E & Döhner H. (2006). Acute myeloid leukaemia. *Lancet.* Vol.368, No.9550, pp.1894-1907.
- Ferrara F & Del Vecchio L. (2002). Acute myeloid leukemia with t(8;21)/AML1/ETO: a distinct biological and clinical entity. *Haematologica.* Vol.87, No.3, pp.306-319.
- Figueroa ME, Lugthart S, Li Y, Erpelinck-Verschueren C et al. (2010). DNA methylation signatures identify biologically distinct subtypes in acute myeloid leukemia. *Cancer Cell.* Vol.17, No.1, pp13-27.
- Foran JM. (2010). New prognostic markers in acute myeloid leukemia: perspective from the clinic. *Hematology Am Soc Hematol Educ Program.* pp.47-55.
- Garcia-Manero G. (2011). Myelodysplastic syndromes: 2011 update on diagnosis, risk-stratification, and management. *Am J Hematol.* Vol.86, No.6, pp.490-498.
- Garcia-Manero, G., Bueso-Ramos, C., Daniel, J., Williamson, J., Kantarjian, H. M., & Issa, J. P. (2002a). DNA methylation patterns at relapse in adult acute lymphocytic leukemia. *Clin.Cancer Res.*, Vol.8, No.6, pp.1897-1903.
- Garcia-Manero, G., Daniel, J., Smith, T. L., Kornblau, S. M., Lee, M. S., Kantarjian, H. M., & Issa, J. P. (2002b). DNA methylation of multiple promoter-associated CpG islands in adult acute lymphocytic leukemia. *Clin.Cancer Res.*, Vol.8, No.7, pp.2217-2224.
- Garcia-Manero, G., Jeha, S., Daniel, J., Williamson, J., Albitar, M., Kantarjian, H. M., & Issa, J. P. (2003). Aberrant DNA methylation in pediatric patients with acute lymphocytic leukemia. *Cancer*, Vol.97, No.3, pp.695-702.
- Glasow A, Barrett A, Petrie K, Gupta R, Boix-Chornet M, Zhou DC, Grimwade D, Gallagher R, von Lindern M, Waxman S, Enver T, Hildebrandt G, Zelent A. (2008). DNA methylation-independent loss of RARA gene expression in acute myeloid leukemia. *Blood.* Vol.111, No.4, pp.2374-2377.
- Godley LA, Cunningham J, Dolan ME, Huang RS et al. (2011). An integrated genomic approach to the assessment and treatment of acute myeloid leukemia. *Semin Oncol.* Vol.38, No.2, pp.215-224.
- Godley LA & Larson RA. (2008). Therapy-related myeloid leukemia. *Semin Oncol.* Vol.35, No.4, 418-429.

- Goto, T. & Monk, M. (1998). Regulation of X-Chromosome Inactivation in Development in Mice and Humans. *Microbiol.Mol.Biol.Rev.*, Vol.62, No.2, pp. 362-378.
- Graux, C., Cools, J., Michaux, L., Vandenberghe, P., & Hagemeijer, A. (2006). Cytogenetics and molecular genetics of T-cell acute lymphoblastic leukemia: from thymocyte to lymphoblast. *Leukemia*, Vol.20, No.9, pp.1496-1510.
- Greaves MF, Maia AT, Wiemels JL, Ford AM. (2003). Leukemia in twins: lessons in natural history. *Blood*. Vol.102, No.7, pp.2321-2333.
- Greaves MF & Wiemels J. (2003). Origins of chromosome translocations in childhood leukaemia. *Nat Rev Cancer*. Vol.3, No.9, pp.639-649.
- Gu, H., Smith, Z. D., Bock, C., Boyle, P., Gnirke, A., & Meissner, A. (2011). Preparation of reduced representation bisulfite sequencing libraries for genome-scale DNA methylation profiling. *Nat.Protoc.*, Vol.6, No.4, pp.468-481.
- Gulley ML, Shea TC, Fedoriw Y. (2010). Genetic tests to evaluate prognosis and predict therapeutic response in acute myeloid leukemia. *J Mol Diagn*. Vol.12, No.1, pp.3-16.
- Gupta V, Tallman MS, Weisdorf DJ. (2011). Allogeneic hematopoietic cell transplantation for adults with acute myeloid leukemia: myths, controversies, and unknowns. *Blood*. Vol.117, No.8, 2307-2318.
- Gutierrez, M. I., Siraj, A. K., Bhargava, M., Ozbek, U., Banavali, S., Chaudhary, M. A., El, S. H., & Bhatia, K. (2003). Concurrent methylation of multiple genes in childhood ALL: Correlation with phenotype and molecular subgroup. *Leukemia*, Vol.17, No.9, pp.1845-1850
- Hanahan D & Weinberg RA. (2011) Hallmarks of cancer: the next generation. *Cell*. Vol.144, No.5, pp.646-674.
- Hanahan, D. & Weinberg, R.A. (2000). The hallmarks of cancer. *Cell*. Vol.100, pp.57-70.
- Hatziapostolou M & Iliopoulos D. (2011). Epigenetic aberrations during oncogenesis. *Cell Mol Life Sci*. Vol.68, No.10, 1681-1702.
- Herman JG & Baylin SB. (2003). Gene silencing in cancer in association with promoter hypermethylation. *N Engl J Med*. Vol.349, No.21, pp.2042-2054.
- Hogan, L. E., Meyer, J. A., Yang, J., Wang, J., Wong, N., Yang, W., Condos, G., Hunger, S. P., Raetz, E., Saffery, R., Relling, M. V., Bhojwani, D., Morrison, D. J., & Carroll, W. L. (2011). Integrated genomic analysis of relapsed childhood acute lymphoblastic leukemia reveals therapeutic strategies. *Blood*.
- Huang, T. H., Perry, M. R., & Laux, D. E. (1999). Methylation profiling of CpG islands in human breast cancer cells. *Hum.Mol.Genet.*, Vol.8, No.3, pp.459-470.
- Huntly BJ & Gilliland DG. (2005). Leukaemia stem cells and the evolution of cancer-stem-cell research. *Nat Rev Cancer*. Vol.5, No.4, pp.311-321.
- Hutter, G., Kaiser, M., Neumann, M., Mossner, M., Nowak, D., Baldus, C. D., Gokbuget, N., Hoelzer, D., Thiel, E., & Hofmann, W. K. (2011). Epigenetic regulation of PAX5 expression in acute T-cell lymphoblastic leukemia. *Leuk.Res.*, Vol.35, No.5, pp.614-619.
- Iravani, M., Dhat, R., & Price, C. M. (1997). Methylation of the multi tumor suppressor gene-2 (MTS2, CDKN1, p15INK4B) in childhood acute lymphoblastic leukemia. *Oncogene*, Vol.15, No.21, pp. 2609-2614.



- Irizarry, R. A., Ladd-Acosta, C., Wen, B., Wu, Z., Montano, C., Onyango, P., Cui, H., Gabo, K., Rongione, M., Webster, M., Ji, H., Potash, J. B., Sabunciyan, S., & Feinberg, A. P. (2009). The human colon cancer methylome shows similar hypo- and hypermethylation at conserved tissue-specific CpG island shores. *Nat.Genet.*, Vol.41, No.2, pp.178-186.
- Issa JP, Baylin SB, Herman JG. (1997). DNA methylation changes in hematologic malignancies: biologic and clinical implications. *Leukemia*. Vol.11 Suppl, No.1:S7-11.
- Jamieson CH, Ailles LE, Dylla SJ, Muijtjens M, Jones C, Zehnder JL, Gotlib J, Li K, Manz MG, Keating A, Sawyers CL, Weissman IL. (2004). Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML. *N Engl J Med*. Vol.351, No.7, pp.657-667.
- Jan M, Chao MP, Cha AC, Alizadeh AA, Gentles AJ, Weissman IL, Majeti R. (2011). Prospective separation of normal and leukemic stem cells based on differential expression of TIM3, a human acute myeloid leukemia stem cell marker. *Proc Natl Acad Sci U S A*. Vol.108, No.12, pp.5009-5014.
- Jimenez-Velasco, A., Roman-Gomez, J., Agirre, X., Barrios, M., Navarro, G., Vazquez, I., Prosper, F., Torres, A., & Heiniger, A. (2005). Downregulation of the large tumor suppressor 2 (LATS2/KPM) gene is associated with poor prognosis in acute lymphoblastic leukemia. *Leukemia*, Vol.19, No.12, pp.2347-2350.
- Kawamoto H, Wada H, Katsura Y. (2010). A revised scheme for developmental pathways of hematopoietic cells: the myeloid-based model. *Int Immunol*. Vol.22, No.2, pp.65-70.
- Kelly LM & Gilliland DG. (2002). Genetics of myeloid leukemias. *Annu Rev Genomics Hum Genet*. Vol.3, pp.179-98.
- Kroeger H, Jelinek J, Estécio MR, He R et al. (2008). Aberrant CpG island methylation in acute myeloid leukemia is accentuated at relapse. *Blood*. Vol.112, No.4, pp.1366-1373.
- Kuang, S. Q., Tong, W. G., Yang, H., Lin, W., Lee, M. K., Fang, Z. H., Wei, Y., Jelinek, J., Issa, J. P., & Garcia-Manero, G. (2008). Genome-wide identification of aberrantly methylated promoter associated CpG islands in acute lymphocytic leukemia. *Leukemia*, Vol.22, No.8, pp.1529-1538.
- Kulis M & Esteller M. (2010). DNA methylation and cancer. *Adv Genet*. Vol. 70, pp.27-56.
- Laird, P. W. (2010). Principles and challenges of genome-wide DNA methylation analysis. *Nat.Rev.Genet.*, Vol.11, No.3, pp.191-203.
- Lapidot T, Sirard C, Vormoor J, Murdoch B, Hoang T, Caceres-Cortes J, Minden M, Paterson B, Caligiuri MA, Dick JE. (1994). A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. *Nature*. Vol.367, pp.645-648.
- Lausten-Thomsen U, Madsen HO, Vestergaard TR, Hjalgrim H, Nersting J, Schmiegelow K. (2011). Prevalence of t(12;21)[ETV6-RUNX1]-positive cells in healthy neonates. *Blood*, Vol.117, No.1, pp.186-189.
- Lechner M, Boshoff C, Beck S. (2010). Cancer epigenome. *Adv Genet*. Vol.70, pp.247-276.
- Ley TJ, Ding L, Walter MJ, McLellan MD et al. (2010). DNMT3A mutations in acute myeloid leukemia. *N Engl J Med*. Vol.363, No.25, pp.2424-2433.
- Li, E., Beard, C., & Jaenisch, R. (1993). Role for DNA methylation in genomic imprinting. *Nature*, Vol.366, No.6453, pp.362-365.



- Licht, J. D. (2006). Reconstructing a disease: What essential features of the retinoic acid receptor fusion oncoproteins generate acute promyelocytic leukaemia? *Cancer Cell*, Vol.9, pp.73-74.
- Lin TC, Hou HA, Chou WC, Ou DL, Yu SL, Tien HF, Lin LI. (2011). CEBPA methylation as a prognostic biomarker in patients with de novo acute myeloid leukemia. *Leukemia*. Vol.25, No.1, pp.32-40.
- Link DC, Schuettpelez LG, Shen D, Wang J et al. (2011). Identification of a novel TP53 cancer susceptibility mutation through whole-genome sequencing of a patient with therapy-related AML. *JAMA*. Vol.305, No.15, pp.1568-1576.
- Link KA, Chou FS, Mulloy JC. (2010). Core binding factor at the crossroads: determining the fate of the HSC. *J Cell Physiol*. Vol.222, No.1, pp.50-56.
- Liu S, Shen T, Huynh L, Klisovic MI, Rush LJ et al. (2005). Interplay of RUNX1/MTG8 and DNA methyltransferase 1 in acute myeloid leukaemia. *Cancer Res*. Vol.65, pp.1277-1284.
- Löwenberg B, Downing JR, Burnett A. (1999). Acute myeloid leukemia. *N Engl J Med*. Vol.341, No.14, pp.1051-1062.
- Lugthart S, Figueroa ME, Bindels E, Skrabanek L, Valk PJ, Li Y, Meyer S, Erpelinck-Verschueren C, Grealley J, Löwenberg B, Melnick A, Delwel R. (2011). Aberrant DNA hypermethylation signature in acute myeloid leukemia directed by EVI1. *Blood*. Vol.117, No.1, pp.234-241.
- Marcucci G, Mrózek K, Bloomfield CD. (2005). Molecular heterogeneity and prognostic biomarkers in adults with acute myeloid leukemia and normal cytogenetics. *Curr Opin Hematol*. Vol.12, No.1, pp.68-75.
- Mardis ER, Ding L, Dooling DJ, Larson DE et al. (2009). Recurring mutations found by sequencing an acute myeloid leukemia genome. *N Engl J Med*. Vol.361, No.11, pp.1058-1066.
- Martin, V., Agirre, X., Jimenez-Velasco, A., Jose-Eneriz, E. S., Cordeu, L., Garate, L., Vilas-Zornoza, A., Castillejo, J. A., Heiniger, A., Prosper, F., Torres, A., & Roman-Gomez, J. (2008). Methylation status of Wnt signaling pathway genes affects the clinical outcome of Philadelphia-positive acute lymphoblastic leukemia. *Cancer Sci*, Vol.99, No.9, pp.1865-1868.
- Martín-Subero JI & Esteller M. (2011). Profiling epigenetic alterations in disease. *Adv Exp Med Biol*. Vol.711, pp.162-77.
- McHale CM & Smith MT. (2004). Prenatal origin of chromosomal translocations in acute childhood leukemia: implications and future directions. *Am J Hematol*. Vol.75, No.4, pp.254-257.
- Melnick AM. (2010). Epigenetics in AML. *Best Pract Res Clin Haematol*. Vol.23, No.4, pp.463-468.
- Metcalf D. (2008). Hematopoietic cytokines. *Blood*. Vol.111, No.2, 485-491.
- Metzker ML. (2010). Sequencing technologies - the next generation. *Nat Rev Genet*. Vol.11, No.1, pp.31-46.
- Milani, L., Lundmark, A., Kiialainen, A., Nordlund, J., Flaegstad, T., Forestier, E., Heyman, M., Jonmundsson, G., Kanerva, J., Schmiegelow, K., Soderhall, S., Gustafsson, M. G., Lonnerholm, G., & Syvanen, A. C. (2010). DNA methylation for subtype

- classification and prediction of treatment outcome in patients with childhood acute lymphoblastic leukemia. *Blood*, Vol.115, No.6, pp.1214-1225.
- Milne E, Royle JA, Miller M, Bower C, de Klerk NH, Bailey HD, van Bockxmeer F, Attia J, Scott RJ, Norris MD, Haber M, Thompson JR, Fritschi L, Marshall GM, Armstrong BK. (2010). Maternal folate and other vitamin supplementation during pregnancy and risk of acute lymphoblastic leukemia in the offspring. *Int J Cancer*. Vol.126, No.11, pp.2690-2699.
- Mori H, Colman SM, Xiao Z, Ford AM, Healy LE, Donaldson C, Hows JM, Navarrete C, Greaves M. (2002). Chromosome translocations and covert leukemic clones are generated during normal fetal development. *Proc Natl Acad Sci U S A*. Vol.99, No.12, pp.8242-8247.
- Mori H, Colman SM, Xiao Z, Ford AM. (2002). Chromosome translocations and covert leukemic clones are generated during normal fetal development. *Proc Natl Acad Sci U S A*. Vol.99, No.12, pp.8242-8247.
- Mrózek K, Harper DP, Aplan PD. (2009). Cytogenetics and molecular genetics of acute lymphoblastic leukemia. *Hematol Oncol Clin North Am*. Vol.23, No.5, pp.991-1010
- Mullighan CG, Goorha S, Radtke I, et al. (2007). Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia. *Nature* vol.446, pp.758-764.
- Musolino C, Sant'antonio E, Penna G, Alonci A, Russo S, Granata A, Allegra A. (2010). Epigenetic therapy in myelodysplastic syndromes. *Eur J Haematol*. Vol.84, No.6, pp.463-473.
- Odenike O, Thirman MJ, Artz AS, Godley LA, Larson RA, Stock W. (2011). Gene mutations, epigenetic dysregulation, and personalized therapy in myeloid neoplasia: are we there yet? *Semin Oncol*. Vol.38, No.2, pp.196-214.
- Oki Y & Issa JP. (2010). Epigenetic mechanisms in AML - a target for therapy. *Cancer Treat Res*. Vol.145, pp.19-40.
- Paixao, V. A., Vidal, D. O., Caballero, O. L., Vettore, A. L., Tone, L. G., Ribeiro, K. B., & Lopes, L. F. (2006). Hypermethylation of CpG island in the promoter region of CALCA in acute lymphoblastic leukemia with central nervous system (CNS) infiltration correlates with poorer prognosis. *Leuk.Res*. Vol.30, No.7, pp.891-894.
- Paschka P. (2008). Core binding factor acute myeloid leukemia. *Semin Oncol*. Vol.35, No.4, pp.410-417.
- Passegué E, Jamieson CH, Ailles LE, Weissman IL. (2003). Normal and leukemic hematopoiesis: are leukemias a stem cell disorder or a reacquisition of stem cell characteristics? *Proc Natl Acad Sci U S A*. Vol.100 Suppl, No.1, pp.11842-11849.
- Peters AH & Schwaller J. (2011). Epigenetic mechanisms in acute myeloid leukemia. *Prog Drug Res*. Vol.67, pp.197-219.
- Popp HD & Bohlander SK. (2010). Genetic instability in inherited and sporadic leukemias. *Genes Chromosomes Cancer*. Vol.49, No.12, pp.1071-1081.
- Pui CH, Carroll WL, Meshinchi S, Arceci RJ. (2011). Biology, risk stratification, and therapy of pediatric acute leukemias: an update. *J Clin Oncol*. Vol.29, No.5, pp.551-565.
- Pui C-H, Relling MV, and Downing JR. (2004). Mechanisms of Disease: Acute Lymphoblastic Leukemia. *N Engl J Med* Vol.350, pp.1535-1548

- Pui CH, Robison LL, Look AT. (2008). Acute lymphoblastic leukaemia. *Lancet*, Vol.371, pp.1030-1043.
- Pui, C. H., Relling, M. V., & Downing, J. R. (2004). Acute lymphoblastic leukemia. *N.Engl.J.Med.*, Vol.350, No.15, pp. 1535-1548.
- Quintás-Cardama A, Santos FP, Garcia-Manero G. (2011). Histone deacetylase inhibitors for the treatment of myelodysplastic syndrome and acute myeloid leukemia. *Leukemia*. Vol.25, No.2, pp.226-235.
- Rauch, T. & Pfeifer, G. P. (2005). Methylated-CpG island recovery assay: a new technique for the rapid detection of methylated-CpG islands in cancer. *Lab Invest*, Vol.85, No.9, pp.1172-1180.
- Razin, A. & Cedar, H. (1994). DNA methylation and genomic imprinting. *Cell*, Vol.77, No.4, pp.473-476.
- Robertson, K. D. & Jones, P. (2000). DNA methylation: past, present and future directions. *Carcinogenesis*, Vol.21, No.3, pp.461-467.
- Roman, J., Castillejo, J. A., Jimenez, A., Bornstein, R., Gonzalez, M. G., del Carmen, R. M., Barrios, M., Maldonado, J., & Torres, A. (2001). Hypermethylation of the calcitonin gene in acute lymphoblastic leukaemia is associated with unfavourable clinical outcome. *Br.J.Haematol.*, Vol.113, No.2, pp.329-338.
- Roman-Gomez, J., Castillejo, J. A., Jimenez, A., Gonzalez, M. G., Moreno, F., Rodriguez, M. C., Barrios, M., Maldonado, J., & Torres, A. (2002). 5' CpG island hypermethylation is associated with transcriptional silencing of the p21(CIP1/WAF1/SDI1) gene and confers poor prognosis in acute lymphoblastic leukemia. *Blood*, Vol.99, No.7, pp.2291-2296.
- Roman-Gomez, J., Jimenez-Velasco, A., Agirre, X., Castillejo, J. A., Navarro, G., Barrios, M., Andreu, E. J., Prosper, F., Heiniger, A., & Torres, A. (2004). Transcriptional silencing of the Dickkopf-3 (Dkk-3) gene by CpG hypermethylation in acute lymphoblastic leukaemia. *Br.J.Cancer*, Vol.91, No.4, pp. 707-713.
- Roman-Gomez, J., Jimenez-Velasco, A., Agirre, X., Castillejo, J. A., Navarro, G., Calasanz, M. J., Garate, L., San Jose-Eneriz, E., Cordeu, L., Prosper, F., Heiniger, A., & Torres, A. (2006). CpG island methylator phenotype redefines the prognostic effect of t(12;21) in childhood acute lymphoblastic leukemia. *Clin.Cancer Res.*, Vol.12, No.16, pp.4845-4850.
- Roman-Gomez, J., Jimenez-Velasco, A., Cordeu, L., Vilas-Zornoza, A., San Jose-Eneriz, E., Garate, L., Castillejo, J. A., Martin, V., Prosper, F., Heiniger, A., Torres, A., & Agirre, X. (2007). WNT5A, a putative tumour suppressor of lymphoid malignancies, is inactivated by aberrant methylation in acute lymphoblastic leukaemia. *Eur.J.Cancer*, Vol.43, No.18, pp.2736-2746
- Rosu-Myles M & Wolff L. (2008). p15Ink4b: dual function in myelopoiesis and inactivation in myeloid disease. *Blood Cells Mol Dis*. Vol.40, No.3, pp.406-409.
- Sahu, G. R. & Das, B. R. (2005). Alteration of p73 in pediatric de novo acute lymphoblastic leukemia. *Biochem.Biophys.Res.Comm.*, Vol.327, No.3, pp.750-755.
- Scholz, C., Nimmrich, I., Burger, M., Becker, E., Dorken, B., Ludwig, W. D., & Maier, S. (2005). Distinction of acute lymphoblastic leukemia from acute myeloid leukemia

- through microarray-based DNA methylation analysis. *Ann.Hematol.*, Vol.84, No.4, pp.236-244.
- Schoofs T & Müller-Tidow C. (2011). DNA methylation as a pathogenic event and as a therapeutic target in AML. *Cancer Treat Rev.* Vol.37 Suppl No.1, pp.S13-8.
- Scott, S. A., Kimura, T., Dong, W. F., Ichinohasama, R., Bergen, S., Kerviche, A., Sheridan, D., & DeCoteau, J. F. (2004). Methylation status of cyclin-dependent kinase inhibitor genes within the transforming growth factor beta pathway in human T-cell lymphoblastic lymphoma/leukemia. *Leuk.Res.*, Vol.28, No.12, pp.1293-1301.
- Shteper, P. J., Siegfried, Z., Asimakopoulos, F. A., Palumbo, G. A., Rachmilewitz, E. A., Ben-Neriah, Y., & Ben-Yehuda, D. (2001). ABL1 methylation in Ph-positive ALL is exclusively associated with the P210 form of BCR-ABL. *Leukemia*, Vol.15, No.4, pp.575-582.
- Siegel R, Ward E, Brawley O, Jemal A. (2011). Cancer statistics 2011, The impact of eliminating socioeconomic and racial disparities on premature cancer deaths. *CA Cancer J Clin.* Vol.61, pp.212-236.
- Silverman LR & Mufti GJ. (2005). Methylation inhibitor therapy in the treatment of myelodysplastic syndrome. *Nat Clin Pract Oncol.* Vol.2 Suppl No.1, pp.S12-23.
- Smith MT, Zhang L, McHale CM, Skibola CF, Rappaport SM. (2011). Benzene, the exposome and future investigations of leukemia etiology. *Chem Biol Interact.* Vol.192, No.1-2, pp.155-159.
- Smith, Z. D., Gu, H., Bock, C., Gnirke, A., & Meissner, A. (2009). High-throughput bisulfite sequencing in mammalian genomes. *Methods*, Vol.48, No.3, pp.226-232.
- Solis EC. (2011). Treatment strategies in patients with core-binding factor acute myeloid leukemia. *Curr Oncol Rep.* Vol.13, No.5, pp.359-360.
- Stam, R. W., den Boer, M. L., Passier, M. M., Janka-Schaub, G. E., Sallan, S. E., Armstrong, S. A., & Pieters, R. (2006). Silencing of the tumor suppressor gene FHIT is highly characteristic for MLL gene rearranged infant acute lymphoblastic leukemia. *Leukemia*, Vol.20, No.2, pp.264-271.
- Sternberg DW & Gilliland DG. (2004). The role of signal transducer and activator of transcription factors in leukemogenesis. *J Clin Oncol.* Vol.22, No.2, pp.361-371.
- Stumpel, D. J., Schneider, P., van Roon, E. H., Boer, J. M., de, L. P., Valsecchi, M. G., de Menezes, R. X., Pieters, R., & Stam, R. W. (2009). Specific promoter methylation identifies different subgroups of MLL-rearranged infant acute lymphoblastic leukemia, influences clinical outcome, and provides therapeutic options. *Blood*, Vol.114, No.27, pp.5490-5498.
- Swerdlow SH, Campo E, Harris NL, et al, eds. (2008). WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC.
- Taberlay PC & Jones PA. (2011). DNA methylation and cancer. *Prog Drug Res.* Vol.67, pp.1-23
- Taniguchi, A., Nemoto, Y., Yokoyama, A., Kotani, N., Imai, S., Shuin, T., & Daibata, M. (2008). Promoter methylation of the bone morphogenetic protein-6 gene in association with adult T-cell leukemia. *Int.J.Cancer*, Vol.123, No.8, pp.1824-1831.
- Taylor, K. H., Kramer, R. S., Davis, J. W., Guo, J., Duff, D. J., Xu, D., Caldwell, C. W., & Shi, H. (2007a). Ultradeep bisulfite sequencing analysis of DNA methylation patterns in




- multiple gene promoters by 454 sequencing. *Cancer Res*, Vol.67, No.18, pp.8511-8518.
- Taylor, K. H., Pena-Hernandez, K. E., Davis, J. W., Arthur, G. L., Duff, D. J., Shi, H., Rahmatpanah, F. B., Sjahputera, O., & Caldwell, C. W. (2007b). Large-Scale CpG Methylation Analysis Identifies Novel Candidate Genes and Reveals Methylation Hotspots in Acute Lymphoblastic Leukemia. *Cancer Res*, Vol.67, No.6, pp.2617-2625.
- Toyota M & Suzuki H. (2010). Epigenetic drivers of genetic alterations. *Adv Genet*. Vol.70, pp.309-323.
- Toyota, M. & Issa, J. P. (2002). Methylated CpG island amplification for methylation analysis and cloning differentially methylated sequences. *Methods Mol.Biol.*, Vol.200, pp.101-110.
- Tsellou, E., Troungos, C., Moschovi, M., Athanasiadou-Piperopoulou, F., Polychronopoulou, S., Kosmidis, H., Kalmanti, M., Hatzakis, A., Dessypris, N., Kalofoutis, A., & Petridou, E. (2005). Hypermethylation of CpG islands in the promoter region of the p15INK4B gene in childhood acute leukaemia. *Eur.J.Cancer*, Vol.41, No.4, pp.584-589.
- Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit A, Harris NL, Le Beau MM, Hellström-Lindberg E, Tefferi A, Bloomfield CD. (2009). The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. *Blood*. Vol.114, No.5, pp.937-951.
- Vilas-Zornoza, A., Agirre, X., Martin-Palanco, V., Martin-Subero, J. I., San Jose-Eneriz, E., Garate, L., Alvarez, S., Miranda, E., Rodriguez-Otero, P., Rifon, J., Torres, A., Calasanz, M. J., Cruz, C. J., Roman-Gomez, J., & Prosper, F. (2011). Frequent and simultaneous epigenetic inactivation of TP53 pathway genes in acute lymphoblastic leukemia. *PLoS.One.*, Vol.6, No.2, p. (e17012),ISSN
- Wang MX, Wang HY, Zhao X, Srilatha N et al. (2010). Molecular detection of B-cell neoplasms by specific DNA methylation biomarkers. *Int J Clin Exp Pathol*. Vol.3, No.3, pp.265-279.
- Wang ZY & Chen Z. (2008). Acute promyelocytic leukemia: from highly fatal to highly curable. *Blood*. Vol.111, No.5, pp.2505-2515.
- Warrell RP Jr, de Thé H, Wang ZY, Degos L. (1993). Acute promyelocytic leukemia. *N Engl J Med*. Vol.329, No.3, pp.177-189.
- Weber, M., Davies, J. J., Wittig, D., Oakeley, E. J., Haase, M., Lam, W. L., & Schubeler, D. (2005). Chromosome-wide and promoter-specific analyses identify sites of differential DNA methylation in normal and transformed human cells. *Nat Genet*, Vol.37, No.8, pp.853-862.
- Welch JS, Westervelt P, Ding L, Larson DE et al. (2011). Use of whole-genome sequencing to diagnose a cryptic fusion oncogene. *JAMA*. Vol.305, No.15, pp.1577-1584.
- Wiemels J, Kang M, Greaves M. (2009). Backtracking of leukemic clones to birth. *Methods Mol Biol*. Vol.538, pp.7-27.
- Wilop S, Fernandez AF, Jost E, Herman JG, Brümmendorf TH, Esteller M, Galm O. (2011). Array-based DNA methylation profiling in acute myeloid leukaemia. *Br J Haematol*. Vol.155, No.1, pp.65-72.
- Wu G, Yi N, Absher D, Zhi D. (2011). Statistical quantification of methylation levels by next-generation sequencing. *PLoS One*. Vol.6, No.6, pp.e21034.



- Yan XJ, Xu J, Gu ZH, Pan CM et al. (2011). Exome sequencing identifies somatic mutations of DNA methyltransferase gene DNMT3A in acute monocytic leukemia. *Nat Genet.* Vol.43, No.4, pp309-315.
- Yang, Y., Takeuchi, S., Hofmann, W. K., Ikezoe, T., van Dongen, J. J., Szczepanski, T., Bartram, C. R., Yoshino, N., Taguchi, H., & Koefler, H. P. (2006). Aberrant methylation in promoter-associated CpG islands of multiple genes in acute lymphoblastic leukemia. *Leuk.Res.*, Vol.30, No.1, pp.98-102.
- Zheng, S., Ma, X., Zhang, L., Gunn, L., Smith, M. T., Wiemels, J. L., Leung, K., Buffler, P. A., & Wiencke, J. K. (2004). Hypermethylation of the 5' CpG island of the FHIT gene is associated with hyperdiploid and translocation-negative subtypes of pediatric leukemia. *Cancer Res.*, Vol.64, No.6, pp.2000-2006.

IntechOpen



## **DNA Methylation - From Genomics to Technology**

Edited by Dr. Tatiana Tatarinova

ISBN 978-953-51-0320-2

Hard cover, 400 pages

**Publisher** InTech

**Published online** 16, March, 2012

**Published in print edition** March, 2012

Epigenetics is one of the most exciting and rapidly developing areas of modern genetics with applications in many disciplines from medicine to agriculture. The most common form of epigenetic modification is DNA methylation, which plays a key role in fundamental developmental processes such as embryogenesis and also in the response of organisms to a wide range of environmental stimuli. Indeed, epigenetics is increasingly regarded as one of the major mechanisms used by animals and plants to modulate their genome and its expression to adapt to a wide range of environmental factors. This book brings together a group of experts at the cutting edge of research into DNA methylation and highlights recent advances in methodology and knowledge of underlying mechanisms of this most important of genetic processes. The reader will gain an understanding of the impact, significance and recent advances within the field of epigenetics with a focus on DNA methylation.

### **How to reference**

In order to correctly reference this scholarly work, feel free to copy and paste the following:

Kristen H. Taylor and Michael X. Wang (2012). DNA Methylation in Acute Leukemia, DNA Methylation - From Genomics to Technology, Dr. Tatiana Tatarinova (Ed.), ISBN: 978-953-51-0320-2, InTech, Available from: <http://www.intechopen.com/books/dna-methylation-from-genomics-to-technology/dna-methylation-in-acute-leukemia->

**INTECH**  
open science | open minds

### **InTech Europe**

University Campus STeP Ri  
Slavka Krautzeka 83/A  
51000 Rijeka, Croatia  
Phone: +385 (51) 770 447  
Fax: +385 (51) 686 166  
[www.intechopen.com](http://www.intechopen.com)

### **InTech China**

Unit 405, Office Block, Hotel Equatorial Shanghai  
No.65, Yan An Road (West), Shanghai, 200040, China  
中国上海市延安西路65号上海国际贵都大饭店办公楼405单元  
Phone: +86-21-62489820  
Fax: +86-21-62489821

© 2012 The Author(s). Licensee IntechOpen. This is an open access article distributed under the terms of the [Creative Commons Attribution 3.0 License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

IntechOpen

IntechOpen